Prenatal corticosteroid treatment and accelerated fetal pulmonary maturation. I. Experimental and pharmacological basis;Corticotherapie antenatale et acceleration de la maturation foetale. I. Donnees experimentales et pharmacologiques

Archives de Pediatrie

Volumn 3, Issue 11, 1996, Pages 1111-1117

  Lacaze Masmonteil, T ^a  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

fetal lung maturation; prenatal corticosteroid treatment; prevention; pulmonary surfactant; respiratory distress syndrome

Indexed keywords

BETAMETHASONE; CORTICOSTEROID; DEXAMETHASONE; HYDROCORTISONE; LUNG SURFACTANT; PHOSPHOLIPID; GLUCOCORTICOID;

DRUG EFFECT; FETUS LUNG MATURATION; GENE EXPRESSION; HUMAN; MORTALITY; PATHOPHYSIOLOGY; PRENATAL DRUG EXPOSURE; RESPIRATORY DISTRESS SYNDROME; REVIEW; ANIMAL; BIOSYNTHESIS; FEMALE; FETOMATERNAL TRANSFUSION; FETUS MATURITY; HYALINE MEMBRANE DISEASE; IN VITRO STUDY; LUNG; METABOLISM; NEWBORN; PHYSIOLOGY; PREGNANCY; PRENATAL CARE; PRENATAL DEVELOPMENT;

ANIMALS; FEMALE; FETAL ORGAN MATURITY; GLUCOCORTICOIDS; HUMANS; HYALINE MEMBRANE DISEASE; INFANT, NEWBORN; LUNG; MATERNAL-FETAL EXCHANGE; PREGNANCY; PRENATAL CARE; PULMONARY SURFACTANTS;

EID: 0030279877     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(96)89519-4     Document Type: Review

References (48)

1. 1 Von Neergaard K. Neue Auffassungen über einen Grundbegriff der Atemmechanik. Die Retracktionskraft der Lunge, abhängig von der Oberflächenspannung in den Alveolen. Z Gesamt Exp Med 1929;66:373-94
2. 2 Pattle RE. Properties, function and origin of the alveolar lining layer. Nature 1955;175:1125-26
3. 3 Clements JA. Dependence of pressure - volume characteristics of lungs on intrinsic surface active material. Am J Physiol 1956;187:592
4. 4 Avery M, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 1959; 97:517-523
5. 5 Van Golde LMG, Battenburg JJ, Robertson B. The pulmonary surfactant system: biochemical aspects and functional significance. Physiol Rev 1988;68:374-455
6. 6 Johansson J, Curstedt T, Robertson B. The proteins of the surfactant system. Eur Respir J 1994;7:372-91
7. 7 Van Golde LMG. Potential role of surfactant proteins A and D in innate lung defense against pathogens. Biol Neonate 1995;67(suppl 1):2-17
8. 8 Lagercrantz H, Slotkin TA. The "stress" of being born. Sci Am 1986;254:100-12
9. 9 Rall L, Pictet R, Githens S, Rutter WJ. Glucocorticoids modulate the in vitro development of the embryonic rat pancreas. J Cell Biol 1977;75:398-409
10. 10 Moog F. The influence of the pituitary-adrenal system on the differenciation of phosphatase in the duodenum of the suckling mouse. J Exp Zool 1953;124:329-46
11. 11 Liggins GC. Premature delivery of foetal lambs infused with glucocorticoids. J Endocrinol 1969;45:515-23
12. 12 Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 1972;50:515-25
13. 13 Avery ME. The argument for prenatal administration of dexamethasone to prevent respiratory distress syndrome. J Pediatr 1984;104:240
14. 14 Ryan CA, Finer NN. Antenatal corticosteroid therapy to prevent respiratory distress syndrome. J Pediatr 1995; 126:317-9
15. 15 Jobe AH, Mitchell BR, Gunkel JH. Beneficial effects of the combined use of prenatal corticosteroids and postnatal surfactant on preterm infants. Am J Obstet Gynecol 1993; 168:508-13
16. 16 Crowley P. Antenatal corticosteroid therapy: A meta-analysis of the randomized trials, 1972-1994. Am J Obstet Gynecol 1995;173:322-35
17. 17 Kitterman JA, Liggins GC, Campos GA et al. Prepartum maturation of the lung in fetal sheep; relation to cortisol. J Appl Physiol 1981;51:384-90
18. 18 Scott SM, Watterberg KL. Effect of gestational age, postnatal age, and illness on plasma cortisol concentrations in premature infants. Pediatr Res 1995;37:112-6
19. 19 Snyder JM, Johnston JM, Mendelson CR. Differentiation of type II cells of human fetal lung in vitro. Cell Tissue Res 1981;220:17-25
20. 20 White E, Shy KK, Benedetti TJ. Chronic fetal stress and the risk of infant respiratory distress syndrome. Obstet Gynecol 1986;67:57-62
21. 21 Tyson JE, Kennedy K, Broyles S, Rosenfeld CR. The small for gestational age infant: accelered or delayed pulmonary maturation? Increased or decreased survival? Pediatrics 1995;95:534-8
22. 22 Blackburn WR, Travers H, Potter M. The role of the pituitary-adrenal-thyroid axes in tung differentiation. I. Studies of the cytology and physical properties of anencephalic fetal rat lung. Lab Invest 1972;26:306-18
23. 23 Sosenko IRS, Lewis PL, Frank L. Metyrapone delays surfactant and antioxydant enzyme maturation in developing rat lung. Pediatr Res 1986;20:672-5
24. 24 Mugila L, Jacobson L, Dikkes P, Majzoub JA. Corticotropin-releasing hormone deficiency reveals major fetal but not adult glucocorticoid need. Nature 1995;373:427-32
25. 25 Cole TJ, Blendy JA, Monaghan AP et al. Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev 1995;9:1608-21
26. 26 Post M, Smith BT. Hormonal control of surfactant metabolism. In: Robertson B, Van Golde LMG, Batenburg JJ, eds. Pulmonary surfactant, from molecular biology to clinical practice. Amsterdam: Elsevier, 1992:379-424
27. 27 Bourbon JR, Fraslon C. Developmental aspects of the alveolar epithelium and the pulmonary surfactant system. In: Bourbon JR, ed. Pulmonary surfactant: biochemical, functional, regulatory, and clinical concepts. Boca Raton : CRC Press, 1991:257-324
28. 28 Farrell PM, Engle MJ, Zachman RD et al. Amniotic fluid phospholipids after maternal administration of dexamethasone. Am J Obstet Gynecol 1983;145:484-90
29. 29 Post M. Maternal administration of dexamethasone stimulates cholinephosphate cytidylyl transferase activity in fetal type II cells. Biochem J 1987;241:291-6
30. 30 Batenburg JJ, Elfring RH. Regulation of fatty acid and phosphatidylcholine synthesis in fetal rat type II cells by glucocorticoid at a pretranslational level. In: Müller B, Von Wichert P, eds. Lung surfactant: basic research in the pathogenesis of lung disorders. Basel: Karger, 1994:62-8
31. 31 Xu ZX, Smart DA, Weinhold PA, Feldman DA. Glucocorticoid induction of fatty acid synthetase mediates the stimulatory effect of the hormone on choline-phosphate cytidylyltransferase activity in fetal rat lung. Biochem Biophys Acta 1990;1044:70-6
32. 32 Post M, Torday JS, Smith BT. Alveolar type II cells isolated from fetal rat lung organotypic cultures synthesize and secrete surfactant-associated phospholipids and respond to fibroblast-pneumonocyte factor. Exp Lung Res 1984;7:53-65
33. 33 Scott JE, Das RM. Production of fibroblast-pneumocyte like factor by fetal rabbit lung fibroblasts: isolation and effects of it and related factors on fetal type II cells in vitro. Life Sci 1993;53:765-74
34. 34 Wang J, Kuliszewski M, Yee W et al. Cloning and expression of glucocorticoid-induced genes in fetal rat lung fibroblasts; transforming growth factor ß3. J Biol Chem 1995; 270:2722-28
35. 35 Schellhase DE, Shannon JM. Effects of maternal dexamethasone on expression of SP-A, SP-B, and SP-C in the fetal rat. Am J Respir Cell Mol Biol 1991;4:304-12
36. 36 Liley HG, White RT, Warr RG et al. Regulation of messager RNAs for the hydrophobic surfactant proteins in human lung. J Clin Invest 1989;83:1191-7
37. 37 Liley HG, White RT, Benson BJ, Ballard PL. Glucocorticoids both stimulate and inhibit production of pulmonary surfactant protein A in fetal human lung. Proc Natl Acad Sci USA 1988;85:9090-100
38. 38 Iannuzzi DM, Ertsey R, Ballard PL. Biphasic glucocorticoid regulation of pulmonary surfactant protein-A: characterization of the inhibitory process. Am J Respir 1993; 264:L236-244
39. 39 McCormick SM, Mendelson CR. Human SP-A1 and SP-A2 genes are differentially regulated during development and by cAMP and glucocorticoids. Am J Physiol 1994;266: L367-L374
40. 40 Frank L, Lewis PL, Sosenko IRS. Dexamethasone stimulation of fetal rat lung antioxidant enzyme activity in parallel with surfactant stimulation. Pediatrics 1985;75:569-74
41. 41 Champigny G, Voilley E, Lingueglia E et al. Regulation of expression of the lung amiloride-sensitive Na+ channel by steroid hormones. EMBO J 1994;13:2177-81
42. 42 Beato M. Gene regulation by steroid hormones. Cell 1989;56:335-44
43. 43 Ballard PL, Granberg JP, Ballard RA. Glucocorticoid levels in maternal and cord serum after prenatal betamethasone therapy to prevent respiratory distress syndrome. J Clin Invest 1975;56:1548-54
44. 44 Ward RM. Drug therapy of the fetus. J Clin Pharmacol 1993;33:780-9
45. 45 Ward RM. Pharmacologic enhancement of fetal lung maturation. In: Pediatrics in perinatology: fetal drug therapy, vol 21. Philadelphia: WB Saunders, 1994:523-42
46. 46 Ballard PL, Liggins GC, Kaplan SL, Grumbach MM. Steroid and growth hormone levels in premature infants after prenatal betamethasone therapy to prevent respiratory distress syndrome. Pediatr Res 1980;14:122-7
47. 47 Teramo K, Hallman M, Raivio KO. Maternal glucocorticoid in unplanned premature labor. Controlled study on the effects of betamethasone phosphate on the phospholipids of the gastric aspirate and on the adrenal cortical function of the newborn infant. Pediatr Res 1980;14: 326-9
48. 48 Bradley BS, Kumar SP, Metha PN, Ezhuthachan SG. Neonatal cushingoid syndrome resulting from serial courses of antenatal betamethasone. Obstet Gynecol 1994;83:869-72